EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release

Simon Comerma-Steffensen iD, Attila Kun, Judit Prat-Duran, Susie Mogensen, Elif Alan Albayrak iD, Rafael Fais iD, Gordon Munro, Dan Peters, Ulf Simonsen iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16362 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024. Written by Simon Comerma-Steffensen and 8 co-authors. Institution: Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark. Major MEDLINE topics: Dopamine, Nitric Oxide, Penile Erection, Rats, Sprague-Dawley. Cited 5 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novo Nordisk Foundation, Independent Research Fund Denmark, Aarhus University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose An estimated 40% of patients with erectile dysfunction have a poor prognosis for improvement with currently available treatments. The present study investigated whether a newly developed monoamine transport inhibitor, IP2015, improves erectile function. Experimental Approach We investigated the effects of IP2015 on monoamine uptake and binding, erectile function in rats and diabetic mice and the effect on corpus cavernosum contractility. Key Results IP2015 inhibited the uptake of 5‐HT, noradrenaline and dopamine by human monoamine transporters expressed in cells and in rat brain synaptosomes. Intracavernosal pressure measurement in anaesthetized rats revealed that IP2015 dose‐dependently increased the number and the duration of spontaneous erections. Whereas pretreatment with the dopamine D 2 ‐like receptor antagonists, clozapine and (−)‐sulpiride, or cutting the cavernosal nerve inhibited IP2015‐induced erectile responses, the phosphodiesterase type 5 inhibitor sildenafil further enhanced the IP2015‐mediated increase in intracavernosal pressure. IP2015 also increased the number of erections in type 2 diabetic db/db mice. Direct intracavernosal injection of IP2015 increased penile pressure, and in corpus cavernosum strips, IP2015 induced concentration‐dependent relaxations. These relaxations were enhanced by sildenafil and blunted by endothelial cell removal, a nitric oxide synthase inhibitor, N G ‐nitro‐ l ‐arginine and a D 1 ‐like receptor antagonist, SCH23390. Quantitative polymerase chain reaction (qPCR) showed the expression of the dopamine transporter in the rat corpus cavernosum. Conclusion and Implications Our findings suggest that IP2015 stimulates erectile function by a central mechanism involving dopamine reuptake inhibition and direct NO‐mediated relaxation of the erectile tissue. This novel multi‐modal mechanism of action could offer a new treatment approach to erectile dysfunction.

Subjects

MeSH terms (MEDLINE)

DopamineNitric OxidePenile ErectionRats, Sprague-DawleyMaleAnimalsRatsMiceHumansMice, Inbred C57BLErectile DysfunctionPiperazinesPenisDose-Response Relationship, Drug

Author keywords

IP2015dopaminedopamine transporterendotheliumerectionmicerats

Substances

DopamineNitric OxidevanoxerinePiperazines

Authors and institutions

  • Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark.
  • Department of Biomedical Sciences/Animal Physiology, Faculty of Veterinary, Central University of Venezuela, Caracas, Venezuela.
  • Initiator Pharma A/S, Copenhagen, Denmark.
  • Department of Pharmacology, Faculty of Pharmacy, Ege University, Izmir, Türkiye.
  • Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Hoba Therapeutics, Copenhagen, Denmark.

ORCID profiles: Simon Comerma-Steffensen, Elif Alan Albayrak, Rafael Fais, Ulf Simonsen

Funding

  • Novo Nordisk Foundation
  • Independent Research Fund Denmark
  • Aarhus University
  • CDCH-UCV
  • Novo Nordisk Fonden
  • Danmarks Frie Forskningsfond
  • Aarhus Universitet
  • Consejo de Desarrollo Científico y Humanístico, Universidad Central de Venezuela

Cite

APA

Comerma-Steffensen, S., Kun, A., Prat-Duran, J., Mogensen, S., Alan Albayrak, E., Fais, R., Munro, G., Peters, D., & Simonsen, U. (2024). A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release. British Journal of Pharmacology. https://doi.org/10.1111/bph.16362

Vancouver

Comerma-Steffensen S, Kun A, Prat-Duran J, Mogensen S, Alan Albayrak E, Fais R, et al. A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release. British Journal of Pharmacology. 2024. doi:10.1111/bph.16362

BibTeX
@article{ComermaSteffensen2024,
  author = {Comerma-Steffensen, Simon and Kun, Attila and Prat-Duran, Judit and Mogensen, Susie and Alan Albayrak, Elif and Fais, Rafael and Munro, Gordon and Peters, Dan and Simonsen, Ulf},
  title = {A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16362}
}
Start for free →